新天药业欣力康胶囊临床试验获批

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its proprietary drug, Xinkang Capsules, aimed at treating cancer-related fatigue [1] Company Summary - Xinkang Capsules are an exclusive proprietary medicine developed by the company, presented in a capsule form with a specification of 0.45g per capsule [1] - The drug is a result of the company's independent research and development efforts in traditional Chinese medicine [1] Industry Summary - The approval for clinical trials indicates a potential advancement in the treatment options available for cancer-related fatigue, which may enhance the company's position in the pharmaceutical market [1]